GIT Flashcards
T/F: Nausea and vomiting may be manifestation of a wide
variety of condition including adverse effects from
medication; systemic disorder or infections; pregnancy;
vestibular dysfunction; CNS infection or increased
pressure
T
SEROTONIN 5-HT3 ANTAGONISTs
Ondansetron, Granisetron, Dolasetron, Palonosteron
Potent antiemetic properties that are mediated in part
through central 5-HT3 receptor
SEROTONIN 5-HT3 ANTAGONIST (Ondansetron, Granisetron, Dolasetron, Palonosteron)
T/F:SEROTONIN 5-HT3 ANTAGONIST (Ondansetron, Granisetron, Dolasetron, Palonosteron) may be used in cancer chemotherapy
T
SEROTONIN 5-HT3 ANTAGONIST that has a serum t1/2 of 4 to 9 hrs and is administered orally or IV
Ondansetron, Granisetron, Dolasetron
SEROTONIN 5-HT3 ANTAGONIST that has greater affinity to the 5-HT3 receptor
Palonosteron
T/F: All SEROTONIN 5-HT3 ANTAGONIST
undergoes hepatic metabolism and are eliminated by
renal and hepatic excretion
T
SEROTONIN 5-HT3 ANTAGONIST does not inhibit ___________
dopamine or muscarinic receptor
blocks the 5-HT3 receptor found on the vomiting center
and on your chemoreceptor trigger zone
SEROTONIN 5-HT3 ANTAGONIST
HISTAMINE ANTAGONISTs
Diphenhydramine, Dimenhydrinate
Meclizine
Weak antiemetic, particularly useful for prevention or
treatment of motion sickness
HISTAMINE ANTAGONIST
1st generation H1 antagonist
Diphenhydramine, Dimenhydrinate
H1 antagonist that has significant anticholinergic properties
Diphenhydramine, Dimenhydrinate
H1 antagonist that may cause Sedation as its side effect
Diphenhydramine, Dimenhydrinate
H1 antihistamine agent with minimal anticholinergic
properties that also causes less sedation
Meclizine
H1 antihistamine agent that is used to prevent motion sickness and the treatment of
vertigo due to labyrinth dysfunction
Meclizine
CORTICOSTEROIDs
Dexamethasone and Methylprednisolone
Enhance the efficacy of 5-HT3 receptor antagonist for
prevention of acute and delayed nausea and vomiting
CORTICOSTEROID
patient experiences N&V within 24 hrs after
taking chemotherapeutic agents
Acute nausea and vomiting
patient experiences
N&V after 24 hrs
Delayed nausea and vomiting
Corticosteroid is usually used in an ______ form
IV
Corticosteroid is useful in __________ regimen
cancer chemotherapeutic
NEUROKININ RECEPTOR ANTAGONISTs
Aprepitant Fosaprepitant
NK1 receptor antagonist have __________ properties that
are mediated through central blockade in the area
_____________
antiemetic; postrema
NK1 may also be given to patients that experiences
Cancer Induces
Nausea and Vomiting (CINV)
Highly selective NK1 receptor antagonist that crosses the
blood-brain barrier and occupies brain NK1 receptor found
in CTZ
Aprepitant
NK1 receptor that has no affinity for serotonin and dopamine or
corticosteroid receptor
Aprepitant
NK1 receptor that is associated with fatigue, dizziness and diarrhea
Aprepitant
Apprepritant is metabolized by ________ and may inhibit the metabolism of
other drugs metabolized by ________
CYP3A4; CYP3A4
Aprepitant is available in
Oral form
Intravenous NK1 formulation that converted within 30 minutes
after infusion to aprepitant (active form)
Fosaprepitant
MUSCARINIC ANTAGONISTs
Hyoscine / Scopolamine
Prototypic muscarinic receptor antagonist
Hyoscine / Scopolamine
Often used in preoperative analgesia, seasickness, motion
sickness, ocular irritation and irritable bowel syndrome
Hyoscine / Scopolamine
Hyoscine / Scopolamine is used as an
antiemetic
Hyoscine / Scopolamine may produce very high incidence of anticholinergic effects when given _____ or ___________
orally or parenterally
DOPAMINE 2 BLOCKERs
Phenothiazine
Droperidol
Antipsychotic agents that can be used for their potent
antiemetic and sedative properties
Phenothiazine
Phenothiazine inhibits _______ and _________receptor
dopamine and muscarinic receptor
Phenothiazine’s sedative properties are due to their
antihistamine activity
Phenothiazine drugs
Prochlorperazine, Promethazine, and Thiethylperazine
Antipsychotic butyrophenone also possess antiemetic
properties due to their central dopaminergic blockade
Droperidol